Identification and urinary excretion of p-chlorophenoxyacetamide, a metabolite of iproclozide, in humans.
The presence of p-chlorophenoxyacetamide was detected in the urine of man receiving iproclozide [1-(p-chlorophenoxyacetyl)-2-isopropylhydrazine]. This new metabolite was identified by combined gas-liquid chromatography-mass spectrometry and by comparison with the synthetic compound. An appropriate procedure for the extraction and quantitation of p-chlorophenoxyacetamide by gas-liquid chromatography on a 5% OV-225-packed column with the 2-butyl analog of iproclozide as an internal standard, has been developed. After 20- and 50-mg single dose oral administrations of iproclozide, 5.2 and 8.3% were slowly excreted in urine as p-chlorophenoxyacetamide within 30.5 and 36 hr. respectively. After 20-mg oral intakes by psychiatric patients, the 24-hr urinary excretion of p-chlorophenoxyacetamide amounted to about 2-4% of the iproclozide dose administered.
D000081:Acetamides / Q000652:urine*; D000328:Adult; D002849:Chromatography, Gas; D006016:Glycolates / Q000378:metabolism*; D006801:Humans; D006834:Hydrazines / Q000378:metabolism; D008297:Male; D013058:Mass Spectrometry; D008996:Monoamine Oxidase Inhibitors / Q000378:metabolism*
D000081:Acetamides; D006016:Glycolates; D006834:Hydrazines; D008996:Monoamine Oxidase Inhibitors; C010474:iproclozide